Download Files:
SHP099 (monohydrochloride)
$79 – $581
Products Details
Product Description
– SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM[1].
Web ID
– HY-100388A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C16H20Cl3N5
Citations
– Acta Pharm Sin B. 11 August 2021.|Cancer Discov. 2018 Oct;8(10):1237-1249. |Cancer Res Commun. 2023 Nov 30.|Cancer Res. 2020 Aug 15;80(16):3413-3423.|Inflammation. 2021 Feb 24.|Open Biol. 2017 May;7(5). pii: 170066.|Patent. US20200330595A1.|ACS Nano. 2023 Aug 14.|Acta Pharm Sin B. 11 August 2021.|Acta Pharm Sin B. 17 February 2022.|Ann Transl Med. 2020 Dec;8(23):1570.|Biochem Biophys Res Commun. 2023 Jul 20.|bioRxiv. 2019 Sep.|Br J Cancer. 2022 Dec 7.|Brain Pathol. 2020 Mar;30(2):373-385.|Cancer Cell Int. 2021 Jul 3;21(1):337.|Cancer Res Commun. August 17 2022.|Cancer Res. 2021 Apr 5;canres.3738.2020.|Cancers (Basel). 2022 May 12;14(10):2377.|Cell Rep. 2019 Aug 27;28(9):2331-2344.e8.|Cell Syst. 2020 Nov 18;11(5):478-494.e9.|Commun Biol. 2020 Mar 17;3(1):128. |Exp Cell Res. 2022 Sep 21;113361.|Exp Mol Med. 2020 Jun;52(6):911-920.|Exp Ther Med. February 22, 2022.|FEBS Open Bio. 2020 Dec;10(12):2578-2587.|Front Immunol. 21 January 2021.|Hematol Oncol. 2023 Oct 24.|Hepatology. 2018 Jul;68(1):333-348.|Hepatology. 2020 Jul;72(1):155-168. |Inflamm Res. 2023 Jun 23.|J Exp Med. 2022 Apr 4;219(4):e20210739.|J Immunol Res. 2020 Jun 19;2020:4598476.|J Immunol. 2021 Sep 1;207(5):1419-1427.|J Orthop Translat. 2022 Feb 17;32:112-120.|MedComm. 04 March 2022.|Microvasc Res. 2022 Jun 4;104397.|Mol Cell. 2021 Oct 7;81(19):4076-4090.e8.|Nat Commun. 2019 Apr 1;10(1):1473. |Nat Commun. 2018 Oct 30;9(1):4507. |Nat Immunol. 2021 Oct 22.|Neuro Oncol. 2019 Nov 4;21(11):1423-1435. |Patent. US20190231805A1.|Patent. US20220380385A1.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Mar.|Sci Rep. 2023 Jun 20;13(1):10041.|Signal Transduct Target Ther. 2022 Sep 12;7(1):317.|SSRN. 2020 May.|Theranostics. 2021 Jan 1;11(2):555-566.|Thromb Res. 2023Jun 5.
References
– [1]Garcia Fortanet J, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. J Med Chem. 2016 Sep 8;59(17):7773-82.|[2]Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535(7610):148-52.|[3]Carmine Fedele, et al. SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer Models. bioRxiv. April 25, 2018.
CAS Number
– 2200214-93-1
Molecular Weight
– 388.72
Compound Purity
– 99.92
SMILES
– NC1=NC(N2CCC(C)(N)CC2)=CN=C1C3=CC=CC(Cl)=C3Cl.Cl
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 4.1 mg/mL (ultrasonic;warming)|H2O : ≥ 2.5 mg/mL
Target
– Phosphatase;SHP2
Pathway
– Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
